摘要
目的:探讨奥美拉唑联合奥曲肽急诊治疗急性上消化道出血患者临床疗效及对PT、APTT、TT的影响。方法:选取2018年6月-2019年12月本院收治的急性上消化道出血患者180例,根据治疗方法不同将患者分为对照组和研究组,各90例。对照组应用奥美拉唑治疗,研究组应用奥美拉唑联合奥曲肽治疗。比较两组的临床治疗效果,出血时间,不良反应发生率以及凝血酶原时间(PT)、凝血活酶时间(APTT)、凝血酶时间(TT)。结果:治疗1周后,研究组的总有效率为91.1%,高于对照组的66.7%(P<0.05)。研究组出血时间短于对照组,肠胃不适、恶心呕吐以及腹痛的不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组的PT、APTT以及TT水平均低于对照组,差异均有统计学意义(P<0.05)。结论:在急性上消化道出血患者中应用奥美拉唑联合奥曲肽急诊治疗,可明显提高临床治疗效果,且不良反应发生率降低,出血时间明显缩短,同时降低了PT、APTT、TT水平,值得推广。
Objective:To explore the effect of Omeprazole combined with Octreotide on the clinical efficacy and PT,APTT,TT in patients with acute upper gastrointestinal hemorrhage.Method:A total of 180 patients with acute upper gastrointestinal bleeding admitted to our hospital from June 2018 to December 2019 were selected,they were divided into control group and study group according to random number table method,90 cases in each group.The control group was treated with Omeprazole,the study group was treated with Omeprazole and Octreotide.The clinical effect,bleeding time,incidence of adverse reactions,prothrombin time(PT),activated partial thromboplastin time,(APTT)and thrombin time(TT)were compared between two groups.Result:After 1 week of treatment,the effective rate of the study group was 91.1%higher than 66.7%of the control group(P<0.05).The bleeding time in the study group was shorter than that in the control group,the incidence of adverse reactions such as gastrointestinal discomfort,nausea,vomiting and abdominal pain were lower than those in the control group,the differences were statistical significance(P<0.05).After treatment,PT,APTT and TT levels in the study group were lower than those in the control group,the differences were statistical significance(P<0.05).Conclusion:Omeprazole combined with octreotide in the emergency treatment of patients with acute upper gastrointestinal hemorrhage can significantly improve the clinical treatment effect,the incidence of adverse events in patients is reduced,bleeding time is significantly shortened,the level of PT,APTT,TT is reduced,which is worth promoting.
作者
于鹏艳
YU Pengyan(Chifeng Hospital,Chifeng 024000,China)
出处
《中国医学创新》
CAS
2021年第9期114-117,共4页
Medical Innovation of China